Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect

Bone Marrow Transplantation

Volumn 44, Issue 5, 2009, Pages 325-326

  Khaled, Y ^a   Mellacheruvu, S ^a   Reddy, P ^a   Peres, E ^a   Mineishi, S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; TACROLIMUS;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG DOSE REGIMEN; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS MYELOMA EFFECT; HUMAN; INTERMETHOD COMPARISON; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; WHOLE BODY RADIATION;

ADULT; FEMALE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 70349143179     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.14     Document Type: Article

References (8)

1. Bensinger WI. Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Baillière's best practice & research. Clin Haematol 2007; 20: 783-795.
2. Miura Y, Azuma T, Kusumi E, Matsumura T, Kami M, Komatsu T. Graft-versus-myeloma effects in reduced-intensity cord blood transplantation. Int J Hematol 2007; 86: 463-465.
3. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936.
4. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F et al. Non-myeloablative allografting for newly diagnosed multiple myeloma: The experience of the Gruppo Italiano Trapianti di Midollo. Blood 2008; e-pub ahead of print December 8.
5. Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008; 112: 3914-3915.
6. Bahlis NJ, Stewart DA, Savoie ML, Brown C, Daly A, Chaudhry A et al Fludarabine-busulfan conditioning and in vivo T-cell depletion with reduced dose of ATG followed by allografting induces durable responses in patients with advanced multiple myeloma with no grade III-IV aGvHD. ASH Annual Meeting Abstracts 2006; 108: 3029.
7. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-1993 and 1994-1998 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-216.
8. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2008; e-pub ahead of print November 13.